John Overdeck’s Altamira Therapeutics Ltd CYTO Stock Holding History

John Overdeck’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40	Closed	-$32K	–	5060
2021 Q3	$32K	Buy	+40	New	+$45.1K	﹤0.01%	4158

Other funds holding CYTO

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

John Overdeck's CYTO Position: Q4 2021 in Review

John Overdeck sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2021, closing a stake of 40 shares — an estimated $32K sold.

John Overdeck first reported a position in CYTO in Q3 2021 and held it in 1 quarter. The position peaked at $32K in Q3 2021. 16 funds tracked by Wall St. Rank hold CYTO as of Q4 2021.

John Overdeck reported no remaining Altamira Therapeutics Ltd position as of Q4 2021 after selling out during the quarter.
John Overdeck sold 40 Altamira Therapeutics Ltd shares in Q4 2021, an estimated $32K.
John Overdeck first reported a position in Altamira Therapeutics Ltd in Q3 2021 and held it in 1 quarter.
John Overdeck's Altamira Therapeutics Ltd position peaked at $32K in Q3 2021.
16 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2021.

Based on Two Sigma Investments's 13F filing for Q4 2021, filed 14 Feb 2022.